An interventional study of Test myopia control lenses (BSL) in Myopia, sponsored by Essilor International. Completed at 1 site in Singapore. Open to participants aged 8 Years to 13 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-13.
Sponsored by Essilor International · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 28 studies in Myopia by EssilorLuxottica — 13 open to participants now, 19 under way, none of them phase 3. Myopia · EssilorLuxottica.
Among the 28 studies in Myopia by EssilorLuxottica, this one is the 17th largest by enrollment, is one of 2 that started in 2022, is one of 28 with no phase, and was the 4th registered.
1,166 studies on the registry are indexed under Myopia; 228 are open to participants now.
Browse Myopia studies →13 of the 28 studies in Myopia by EssilorLuxottica are open now, in 4 countries. Recruiting first, the newest first:
Essilor International · Sites in Singapore
Ages 6–13
Essilor International · Sites in France
Ages 12–17 · Healthy volunteers
Essilor International · Sites in France
Ages 6–14
Essilor International · Sites in France
Ages 6–12 · Healthy volunteers
Essilor International · Sites in Singapore
Ages 6–11
By country, each count listing its studies:
Of the 124 Myopia studies recruiting now, 20 (16%) set no upper age limit and 103 (83%) stop at 75 or younger; 85 take children under 18; 53 take healthy volunteers.
This study: 8 Years to 13 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
28 studies; the count open now beside each. This study's row is marked.
First in 2003; this study’s year is marked. 2 started in 2022.
This study's enrollment of 40 is below the median of 79 across 929 interventional studies indexed under Myopia.
Median enrollment 52 across the 28 interventional studies. Of the 9 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Essilor International, one of the names counted as EssilorLuxottica. Under that name alone:
Essilor International is the lead sponsor of 39 studies on the registry; 19 are open to participants now.
6 of the studies in Myopia by EssilorLuxottica that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07440134Essilor InternationalVisual and Postural Behavior in Myopic and Non-Myopic Teenagers | 2027-05 |
| NCT06263946Essilor InternationalEssilor® Stellest® Lenses Multicentre European Study (SLOMES) | 2027-05-04 |
| NCT07297810Essilor InternationalDevelopment of a New Device and Method to Assess the Degree of Myopia and/or Astigmatism in Myopic People | 2027-06 |
| NCT06850168Essilor InternationalClinical Investigation of a Novel Spectacle Lens on Slowing Down Juvenile Myopia Progression | 2027-10 |
| NCT07844408Essilor InternationalStudy of Eye Fatigue From Digital Screens and Its Impact on Visual Performance in People With Normal Vision and Myopia, With and Without Dry Eye Symptoms and Signs | 2027-11 |
Add all 6 to your calendar (.ics) → With an account.
Among the 28 studies in Myopia by EssilorLuxottica, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a mono-centre, prospective, one-arm, unmask clinical trial to evaluate the effectiveness of test lens in slowing myopia progression with respect to axial length elongation compared to a single vision spectacle lens from the historical control group of another clinical trial NCT05331378. A total of 40 children will be recruited.
As myopia is a growing worldwide problem, it is important to better understand the range of possible treatments to slow the progression of myopia. Spectacle lenses with aspherical lenslets were shown to be effective in reducing myopia progression and axial length elongation in children in the previous clinical trial (Bao et al. 2022). A dose-dependent effect was demonstrated, with higher lenslet asphericity having greater myopia control efficacy.
This open clinical trial will test the safety and effectiveness of a test lens designed to modify the area and amount of myopic defocus on the retina without compromising vision. The study population includes children in Singapore aged 8 to 13 years (40 subjects) at the time of commencing treatment. Axial length and spherical equivalent refraction will be the primary measure for myopia progression. Visual acuities will also be compared between test lenses and control lenses of the historical control group to determine the quality of vision using test lenses
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Myopia control spectacle lenses (test lenses) will be given to subjects throughout the 24 months trial.
Device: Test myopia control lenses (BSL)
Myopia control spectacle lenses (test lenses) will be given to subjects throughout the 24 months trial.
Axial Length
Change in ocular axial length (mm)
Time frame: 12 months and 24 months
Axial Length
Change in ocular axial length (mm)
Time frame: 6 months and 18 months
Spherical Equivalent Refraction
Change in spherical equivalent refraction (Dioptres) through manifest subjective refraction.
Time frame: 6 months, 12 months, 18 months and 24 months
Ran from Sep 2022 to primary completion in Feb 2025, 29 months.
Of 236 industry-sponsored interventional studies with no phase under Myopia, half reached primary completion within 6 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 24. This study's 29 months is above that.
Counting every sponsor, half of 438 studies reached it within 14 months; a quarter within 3 and three quarters within 34.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 13, 2026: primary completion Dec 2024 → Feb 2025 and completion Dec 2024 → Feb 2025.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.